RecruitingNCT06172660

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Sponsor

Yale University

Enrollment

3,750 participants

Start Date

Oct 28, 2024

Study Type

OBSERVATIONAL

Conditions

RSV Infection

Summary

The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?

Eligibility

Max Age: 12 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nirsevimab for people with rsv infection. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 12 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.